State Bank of Lizton Acquires Indiana Business Bank LIZTON,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
State Bank of Lizton Acquires Indiana Business Bank

LIZTON, Ind. and INDIANAPOLIS, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Lizton Financial Corporation (“Lizton”) and Indiana Business Bancorp (OTCQB:IBBI) (“IBB”) announced the completion of Lizton’s acquisition of IBB today.  In this transaction, Indiana Business Bank, a wholly-owned subsidiary of IBB, was merged with State Bank of Lizton, a wholly-owned subsidiary of Lizton.  The combined bank will operate as State Bank of Lizton.  The transaction was approved by IBB shareholders and regulators. 

Originally founded in 1910, Lizton is a locally owned, independent commercial bank holding company serving nine communities in Central Indiana through eleven locations. Founded in 2004, IBB has served the business banking needs of Central Indiana through a single Northern Indianapolis location.  All IBB customers will be served by the 11 State Bank of Lizton physical locations after closing of the IBB location on October 21.  Based upon current financials, the combined financial institution will have assets of approximately $440 million.

Michael L. Baker, President and Chief Executive Officer of Lizton Financial Corporation, said,

“We have spent months preparing for the integration of the two banks and we are confident that the IBB customers will experience a smooth transition of their business to State Bank of Lizton.  We are excited to welcome them to our family of customers and to welcome the employees of IBB to State Bank of Lizton also.  They will complement our existing staff and help us build even more expertise to serve our growing customer base.” 

James S. Young, President and Chief Executive Officer of Indiana Business Bancorp, stated,

“We are very excited to continue serving our clients as part of the Lizton family. We want to assure our valued customers that we will still be here to serve them just as we have been before, even our phone numbers will remain the same.  However, our capacity to serve our customers will be expanded now and our customers can expect a broader array of banking products, services and technology."  

State Bank of Lizton is an independently owned and operated community bank with 11 full service locations throughout Hendricks and Boone Counties with offices in Avon, Brownsburg (2), Plainfield, Lizton and Pittsboro in Hendricks County and in Lebanon (2), Zionsville, Jamestown and Dover in Boone County.   State Bank of Lizton offers a full line of personal and commercial banking services.   To learn more, you may visit any SBL location, call 866-348-4674 or find us on the web at www.statebankoflizton.com .

Forward Looking Statement

This press release contains certain forward-looking statements. These statements include, but are not limited to, the respective descriptions of IBB and Lizton’s financial condition, results of operations, asset and credit quality trends, profitability and statements about the expected financial benefits and other effects of the affiliation between the companies. Forward-looking statements can be identified by the use of the words “anticipate,” “believe,” “expect,” “intend,” “could” and “should,” and other words of similar meaning. These forward-looking statements express management’s current expectations or forecasts of future events and, by their nature, are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those in such statements. Factors that might cause such a difference include, but are not limited to: expected cost savings, synergies and other financial benefits from the affiliation might not be realized within the expected time frames and costs or difficulties relating to integration matters might be greater than expected; market, economic, operational, liquidity, credit and interest rate risks associated with the combined entity’s businesses; competition; government legislation and policies; the ability of the combined entity to execute its business plan; changes in the economy which could materially impact credit quality trends and the ability to generate loans and gather deposits; failure or circumvention of internal controls; failure or disruption of information systems; significant changes in accounting, tax or regulatory practices or requirements; new legal obligations or liabilities or unfavorable resolutions of litigations; conditions to the closing of the merger, including the obtaining of required regulatory and shareholder approvals; the merger may involve unexpected costs, liabilities or delays; the occurrence of any event, change or other circumstances that could give to the termination of the merger agreement; and the ability of the parties to recognize the benefits of the merger. These forward-looking statements are made only as of the date of this press release, and neither IBB nor Lizton undertake an obligation to release revisions to these forward-looking statements to reflect events or conditions after the date of this release.

Lizton Financial Corporation Contact Information: Michael L. Baker, President & Chief Executive Officer, 317-858-6182

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading